Featured
-
-
Review Article |
Humanized mouse models for immuno-oncology research
Preclinical models that faithfully recapitulate interactions between the human immune system and tumours are necessary to evaluate human-specific immunotherapies in vivo; however, their number is currently limited. The authors of this Review discuss the currently available humanized mouse models, which are immunodeficient mice co-engrafted with human tumours and immune components, with a focus on their applicability in translational research.
- Jane Chuprin
- , Hannah Buettner
- & Michael A. Brehm
-
Review Article |
Integrating evolutionary dynamics into cancer therapy
Most systemic cancer therapies are administered at doses at or close to the maximum tolerated dose until disease progression. However, this approach usually leads to treatment resistance and fails to take into account several potentially relevant evolutionary principles. In this Review, the authors describe how existing approaches to cancer therapy might be optimized by incorporating an understanding of evolutionary dynamics into cancer therapy.
- Robert A. Gatenby
- & Joel S. Brown
-
Consensus Statement
| Open AccessGlobal Consultation on Cancer Staging: promoting consistent understanding and use
Attempts to incorporate additional criteria into the traditional tumour-node-metastasis staging classification have often resulted in inaccuracy and confusion in the use of terminology. In this Position paper, the authors provide guidance on the consistent use of the terminology relating to cancer staging.
- James Brierley
- , Brian O’Sullivan
- & Mary Gospodarowicz
-
Correspondence |
Assembling the brain trust: the multidisciplinary imperative in neuro-oncology
- Ethan B. Ludmir
- , Anita Mahajan
- & Mary Frances McAleer
-
Correspondence |
Reply to ‘Assembling the brain trust: the multidisciplinary imperative in neuro-oncology’
- Kenneth Aldape
- , Kevin M. Brindle
- & Richard J. Gilbertson
-
-
Consensus Statement
| Open Access
Challenges to curing primary brain tumours
Brain cancer encompasses a diverse range of complex malignancies, many of which are associated with a poor prognosis and require more effective treatments. In this Position Paper, an international panel of clinicians and laboratory-based scientists convened by Cancer Research UK identify and discuss seven challenges that must be overcome if we are to cure all patients with a brain tumour.
- Kenneth Aldape
- , Kevin M. Brindle
- & Richard J. Gilbertson
-
-
-
Research Highlight |
Cancer's vast secretes revealed—secretome changes promote resistance to therapy
- David Killock
-
-
Research Highlight |
Can the mitochondrial adverse effects of antibiotics be exploited to target cancer metabolism?
- David Killock
-
-
-
-
Review Article |
Cancer Systems Biology: a peek into the future of patient care?
Systems biology approaches are beginning to provide information that will enable a more complete view of how the genomic and epigenetic aberrations in cancer cells can alter the homeostasis of signalling networks within the tumour and surrounding microenvironment, both at the organ and organism level. This Review describes the potential of these systems-based approaches and how they are becoming vital for the development and implementation of effective drug discovery and personalized cancer therapy.
- Henrica M. J. Werner
- , Gordon B. Mills
- & Prahlad T. Ram
-
-
-
-
-
Review Article |
Patient-derived tumour xenografts as models for oncology drug development
In this Review, Tentler et al. present the opportunities and challenges of using patient-derived tumour xenograft models in oncology drug development, provide specific disease examples, and describe concepts regarding predictive biomarker development and future applications.
- John J. Tentler
- , Aik Choon Tan
- & S. Gail Eckhardt
-
Functional precision oncology using patient-derived assays: bridging genotype and phenotype
CTCs ‘piggyback’ off neutrophils
DNA polymerase θ—a new target for synthetic lethality?
Antifungal treatment for glioma?
Nerves linked to prostate cancer
High drug attrition rates—where are we going wrong?